GALT

Quote

Short

News

Articles

Message Board

Galectin Therapeutics Inc. (NASDAQ : GALT ) News

Galectin Therapeutics Inc. (NASDAQ: GALT) News Releases

GALT News Releases

May 27, 2026 08:00:00 am

GlobeNewswire

Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin's Potential to Modify Disease Progression in Advanced MASH Cirrhosis

May 15, 2026 08:16:11 am

SeekingAlpha

Galectin Therapeutics GAAP EPS of -$0.08 misses by $0.02

May 15, 2026 08:00:00 am

GlobeNewswire

Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update

May 11, 2026 08:00:00 am

GlobeNewswire

Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology

March 31, 2026 08:05:25 am

SeekingAlpha

Galectin Therapeutics GAAP EPS of -$0.48 beats by $0.01

March 31, 2026 08:00:00 am

GlobeNewswire

Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update

March 17, 2026 08:00:00 am

GlobeNewswire

Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.

March 10, 2026 02:30:26 pm

SeekingAlpha

Galectin Therapeutics Inc. (GALT) Discusses Updated Results for Belapectin in Treatment of MASH Cirrhosis and Portal Hypertension Transcript

February 26, 2026 04:05:00 pm

GlobeNewswire

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET

January 19, 2026 12:32:00 am

TMX Newsfile

Ongoing Investigation into Galectin Therapeutics Inc. (GALT): Contact Levi & Korsinsky About Potential Fraud

	Next 10

Subscribe to Our Newsletter

Download The Market Wire News App

Link Market Wire News to Your X Account